October 31, 2024
TOPLINE: Fidanacogene elaparvovec gene therapy reduced the annualized bleeding rate by 71% in patients with hemophilia B. Factor IX activity levels were sustained at 26.9% at […]
October 31, 2024
TOPLINE: Trastuzumab duocarmazine (T-Duo) improved progression-free survival to 7.0 months compared with 4.9 months with a physician’s choice in advanced human epidermal growth factor receptor 2–positive […]
October 31, 2024
TOPLINE: Patients with cutaneous lupus erythematosus (CLE) experienced improved symptoms with iberdomide, a cereblon modulator, added to standard lupus medications, particularly in subacute and chronic cases. […]
October 31, 2024
TOPLINE: Patients with erythropoietic protoporphyria (EPP) have a higher prevalence of low bone mineral density (BMD) than the general healthy population, but BMD improves with cholecalciferol […]
October 30, 2024
TOPLINE: Poor sleep quality in early middle age is associated with signs of accelerated brain aging in late middle age, a new study shows. Investigators say […]
October 30, 2024
TOPLINE: Approximately 1% of neonates born to O+, antibody-negative mothers qualified for phototherapy within 24 hours of birth, with most identified through routine bilirubin screening. The […]
October 30, 2024
TOPLINE: Combining thoracic radiotherapy with first-line EGFR tyrosine kinase inhibitor (TKI) therapy improves progression-free survival by 6.5 months and overall survival by more than 8 months […]
October 30, 2024
TOPLINE: Hearing loss is associated with a 26% higher risk for Parkinson’s disease (PD), although hearing aids helped mitigate the risk, a new study shows. METHODOLOGY: […]
October 30, 2024
TOPLINE: Having a diagnosis of dementia is associated with an increase in emergency department (ED) visits in the United States, highlighting a potential health crisis and […]